References
Breunig F, Knoll A, Wanner C (2003) Enzyme replacement therapy in Fabry disease: clinical implications. Curr Opin Nephrol Hypertens 12:491–495
Desnick RJ, Eng CM, Ioannou YA (2001) αGalactosidase, a deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw Hill, New York, pp 3733–3774
Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338–346
Desnick RJ, Brady RO (2004) Fabry disease in childhood. J Pediatr 144:S20–6
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ (2001) Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345 : 9–16
Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249–254
Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I, Gal A, Beck M (2003) The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 162:767–772
Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113 : 112–119
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Eggert, A.O., Wössner, R., Knoll, A. et al. Umbilical angiectases as the sole clinical sign of Fabry disease in a 9-year-old boy. Eur J Pediatr 165, 205–206 (2006). https://doi.org/10.1007/s00431-005-0029-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-005-0029-4